Ratings iRhythm Technologies, Inc.

Equities

IRTC

US4500561067

Real-time Estimate Cboe BZX Other stock markets 03:48:49 2024-04-24 pm EDT			5-day change	1st Jan Change
116.9 ^USD	+0.52%		+5.18%	+9.55%

Mar. 08	IRhythm Technologies Closes $661 Million Notes Offering	MT
Mar. 05	Irhythm Technologies Insider Sold Shares Worth $360,983, According to a Recent SEC Filing	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
IRHYTHM TECHNOLOGIES, INC.	+8.91%	3.62B		B-
EKF DIAGNOSTICS HOLDINGS PLC	-12.32%	156M		D
MEDIANA CO.,LTD	-12.92%	84.64M	-	-
NEUROTECH INTERNATIONAL LIMITED	+30.43%	54.69M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes